Abstract
Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Current Signal Transduction Therapy
Title: Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways
Volume: 1 Issue: 1
Author(s): Yann Verdier and Botond Penke
Affiliation:
Keywords: Misfolded protein, beta-amyloid, receptor mediation, signal transduction, neurodegenerative disorders
Abstract: Polypeptides and proteins may undergo misfolding processes resulting in aggregates: oligomers and fibrils possessing toxic properties. In most cases a beta-structure will be formed with high tendency to form suprachemical structures, assemblies. The aggregation grade might play crucial role in the biological activities of protein assemblies. Protein aggregates bind to receptors or receptor complexes of neuronal and glial cells and activate signal transduction pathways. Beta amyloid may interact with Wnt receptors as well as increases the intracellular Ca-ion level in neurons. GSK-3beta activation causes tau-hyperphosphorylation and collaps of the microtubular system. β-amyloid triggers also a CD36 dependent signaling cascade and activates microglia. Other misfolded protein assemblies of alpha-synuclein, huntingtin and prion proteins similarly interact with receptor complexes and disturb signal transduction. Rational drug design may start after understanding these signalisation disturbances. Novel drugs will prevent receptor interaction with misfolded protein aggregates.
Export Options
About this article
Cite this article as:
Verdier Yann and Penke Botond, Polypeptide and Protein Aggregates with Neurotoxic Properties in Neurodegenerative Disorders: Emphasis on β-Amyloid-Induced Dysfunction of Receptor-Mediated Signal Transduction Pathways, Current Signal Transduction Therapy 2006; 1 (1) . https://dx.doi.org/10.2174/157436206775269208
DOI https://dx.doi.org/10.2174/157436206775269208 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology State Dissociation, Human Behavior, and Consciousness
Current Topics in Medicinal Chemistry Chitosan Formulations as Carriers for Therapeutic Proteins
Current Drug Discovery Technologies The Endocannabinoid System in Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Early Tau Pathology Involving the Septo-Hippocampal Pathway in a Tau Transgenic Model: Relevance to Alzheimers Disease
Current Alzheimer Research Recent Advances on the Role of Neurogenesis in the Adult Brain: Therapeutic Potential in Parkinson's and Alzheimer's Diseases
CNS & Neurological Disorders - Drug Targets Structural Changes in Alzheimers Disease Brain Microvessels
Current Alzheimer Research Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Commentary [Research Highlights (Making Sense Out of Antisense in Huntington’s Disease)]
CNS & Neurological Disorders - Drug Targets Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Gene Therapy in Peripheral Nerve Reconstruction Approaches
Current Gene Therapy Role of Metal Ions in the Aβ Oligomerization in Alzheimers Disease and in Other Neurological Disorders
Current Alzheimer Research Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Protein Interaction Studies for Understanding the Tremor Pathway in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Oxidative Status in Multiple Sclerosis and Off-Targets of Antioxidants: The Case of Edaravone
Current Medicinal Chemistry New Therapeutic Property of Dimebon as a Neuroprotective Agent
Current Medicinal Chemistry Current View from Alzheimer Disease to Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets